Covid vaccine maker Moderna, Inc. (MRNA) reported Thursday that its second-quarter net loss was $1.38 billion, compared to net income of $2.20 billion a year ago.
Loss per share was $3.62, compared to earnings per share of $5.24 for the second quarter of 2022.
On average, 15 analysts polled by Thomson Reuters expected loss of $4.04 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the second quarter of 2023 was $344 million, sharply lower than $4.75 billion in the same period in 2022, mainly due to a decrease in sales of COVID-19 vaccine. The Street expected revenues of $319.64 million for the quarter.
Product sales were $293 million, a decrease of 94 percent, primarily driven by lower sales volume.
Looking ahead for fiscal 2023, the company said it is on track to deliver COVID-19 vaccine sales of $6 billion to $8 billion, depending on Covid vaccination rates in the U.S.
Total expected 2023 sales are comprised of around $4 billion from existing APAs and $2 billion to $4 billion from additional sales to the U.S., Japan, EU and other countries.
Sales will be subject to the timing of regulatory approvals, with the Company currently expecting a 2023 second half sales split of approximately 30 percent in the third quarter and 70 percent in the fourth quarter.
In pre-market activity on Nasdaq, Moderna shares were trading at $113.65, up 3 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.